Adenocarcinoma/terapia; Neoplasias Colorrectales/terapia; Inhibidores de Puntos de Control Inmunológico; Proteínas de Punto de Control Inmunitario/inmunología; Inmunoterapia/métodos; Receptores Inmunológicos/antagonistas & inhibidores; Adenocarcinoma/inmunología; Adenocarcinoma/patología; Secuencias de Aminoácidos; Animales; Antígenos CD/inmunología; Sistemas CRISPR-Cas; Neoplasias Colorrectales/inmunología; Neoplasias Colorrectales/patología; Neoplasias Colorrectales/radioterapia; Terapia Combinada; Microbioma Gastrointestinal; Regulación Neoplásica de la Expresión Génica; Humanos; Ratones; Pronóstico; Dominios Proteicos; Receptores Inmunológicos/biosíntesis; Receptores Inmunológicos/deficiencia; Receptores Inmunológicos/genética; Receptores Inmunológicos/inmunología; Microambiente Tumoral

AML acute myelogenous leukemia; APCs antigen-presenting cells; CAFs cancer-associated fibroblasts; CRC colorectal cancer; DC Dendritic Cells; DFS disease-free survival; EMT epithelial-mesenchymal transition; ETBF Bacteroides fragilis; F. nucleatum Fusobacterium nucleatum; Fgl2 fibrinogen-like protein 2; Grb2 growth factor receptor-bound protein 2; IBD inflammatory bowel diseases; ICIs Immune checkpoint inhibitors; IHC immunohistochemistry; List of Abbreviations and symbols:; MAPK mitogen-activated protein kinase; MDSCs myeloid-derived suppressor cells; MSI Microsatellite instability; MSS microsatellite-stable; NFκB nuclear factor-kappa B; NK Natural Killer cell; NSCLC non-small cell lung cancer; PI3K phosphoinositide 3-kinase; PVR poliovirus receptor; RR-MS relapsing-remitting multiple sclerosis; SHIP1 SH2 domain-containing inositol-5-phosphatase 1; TAMs tumor-associated macrophages; TANs tumor-associated neutrophils; TFH follicular helper T cells; TFR follicular regulatory T cells; TIGIT; TIGIT T cell immunoglobulin and ITIM domain; TILs tumor-infiltrating lymphocytes; TME tumor microenvironment; TNM staging spread of cancer to other parts of the body; Tregs regulatory T cells; cancer immunotherapy; colorectal cancer; dMMR defective DNA mismatch repair; immune checkpoint; mAb monoclonal antibody